Novartis, AbbVie and PhRMA secure 340B court win in West Virginia
Novartis, AbbVie and industry group PhRMA on Tuesday notched a victory over a West Virginia law that would have required the companies to distribute drugs at reduced prices to an unlimited number of...
View ArticleUS drug spending surged to almost $450B in 2023
Popular weight loss and diabetes treatments contributed to a “faster overall growth” in prescription drug spending last year, according to a new report from the Centers for Medicare & Medicaid...
View ArticleDavid Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field
David Epstein has retired three times. And he quickly went to work when he got back in the saddle earlier this fall as CEO and chair of Ottimo Pharma, a preclinical biotech trying to take ...
View ArticleSangamo strikes brain-targeting AAV partnership with Astellas
Sangamo has made another gene therapy deal to keep the lights on for a few more months, extending its funding by another three months until at least mid-2025. On Thursday, the struggling California...
View ArticleRoche’s Parkinson’s drug flunks second mid-stage trial
Roche’s alpha-synuclein-targeting antibody has failed to slow the progression of motor symptoms in a mid-stage Parkinson’s disease test, marking the latest setback in a largely challenging year for the...
View ArticleEx-Color Health execs raise $10M to bring AI to pharma
Employees Nos. 1 and 2 of the $4.6 billion health tech startup Color Health have started their own company, aiming to tackle pharma's regulatory burden with generative AI. The San Francisco-based...
View ArticleVertex’s non-opioid pill disappoints in mid-stage chronic pain study
Vertex Pharmaceuticals announced highly anticipated results from a Phase 2 trial Thursday morning in a chronic pain condition, saying its non-opioid pain pill suzetrigine met the primary endpoint and...
View ArticleEndpoints winners and losers 2024: Best and worst biotech trends
Last year’s Endpoints News winners and losers list was such a hit that we decided to make it a tradition. As always, we’re keeping track of who’s ⬆️ and who’s ⬇️ in biopharma, the ideas ...
View ArticleHealth tech industry predicts cautious funding optimism in 2025
After a tough few years, healthcare startups are entering 2025 with cautious optimism. Twelve months ago, early-stage startups faced a funding cliff. Many didn’t survive: Across industries, more...
View ArticleSorriso claims a Phase 1b success for oral antibody in ulcerative colitis
A private startup from Salt Lake City aiming to develop oral antibodies says it has succeeded in an early trial, a potentially significant scientific advancement in a world where systemic treatments...
View ArticleBristol Myers pays $100M upfront to collaborate with Leqembi originator in...
Bristol Myers Squibb is partnering with the original developer of Leqembi in a new Alzheimer’s disease deal. The large drugmaker said Thursday that it's giving BioArctic $100 million upfront to license...
View ArticleLonza expands capsule footprint; BioCentriq's new HQ
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza is expanding its manufacturing sites in ...
View ArticleIn blow to compounders, FDA reaffirms tirzepatide shortage is over
The FDA has reaffirmed that the shortage of Eli Lilly’s blockbuster obesity and diabetes medications is resolved, dealing a blow to pharmacies and telehealth services that have capitalized on providing...
View ArticleGilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug
Plus, news about Abilita Therapeutics, Orion, Novartis, XGEN Venture, Palleon, Henlius, TigaTx, HERVolution Therapeutics and Krystal Biotech: Gilead now owns 30% of Assembly Biosciences: The drugmaker...
View ArticleWhat health tech startups can expect in 2025
This week, Shelby and I looked at the state of health tech funding as we head into next year. In our conversations with investors and bankers, we found some cautious ...
View ArticleRegeneron forges ahead in factor XI despite field’s mixed results
Regeneron will start a “broad” Phase 3 program next year for its two factor XI antibodies, following open-label Phase 2 results for the experimental anti-clotting drugs. The company
View ArticlePayers generally meet drug price watchdog's 'fair access' standards, report says
The Institute for Clinical and Economic Review said major insurers’ drug coverage policies generally do align with the pricing watchdog's set of "fair access" standards, according to a report released...
View ArticleMesoblast wins long-awaited approval for cell therapy
Mesoblast’s stock surged on Thursday after the company won FDA approval for its twice-rejected graft-versus-host disease therapy. Remestemcel-L is the first mesenchymal stromal cell therapy to be...
View ArticleXcovery nabs first FDA approval for lung cancer drug
The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung...
View ArticleFDA rejects Zealand Pharma's short bowel syndrome drug
The FDA rejected Zealand Pharma’s short bowel syndrome drug, and asked the company to run another trial before it reconsiders. The FDA told Zealand it wanted an additional test to “provide further...
View Article